Recent developments include a reported Q3 profit decline, insider buying activity, trading halts and resumptions, and strategic exploration including a potential Celle subsidiary spinoff.

• Cryo-Cell International reported a drop in Q3 profit in October 2025 [N1].
• Insider buying activity was reported in September and August 2025, indicating insider confidence [N2][N3].
• An earnings preview in April 2025 highlighted recent insider trading and hedge fund activity [N4].
• Trading of Cryo-Cell shares was halted and then resumed in late October 2024 due to volatility [N6][N5].
• In March 2024, the company announced plans to explore strategic alternatives and a potential spinoff of its Celle subsidiary [N8].

Cryo-Cell benefits from its long-standing market presence, extensive specimen inventory, and advanced processing and storage technology, which support its leadership in private cord blood banking. The company's FDA-compliant and accredited facilities provide a strong foundation for quality and trust. Expansion into public cord blood banking and third-party storage services (ExtraVault) diversifies revenue streams. The company’s marketing efforts and international licensing agreements enhance growth potential. If the Duke License Agreement dispute resolves favorably, the company could resume development of biopharmaceutical manufacturing and clinical services, potentially expanding its business units.

The termination of the Duke License Agreement has paused Cryo-Cell's expansion into biopharmaceutical manufacturing and clinical infusion services, creating uncertainty around these growth initiatives. The company faces competitive pressures from public cord blood banks and potential regulatory changes that could impact operations. Market penetration remains limited by consumer awareness and cost perceptions. Operational risks include facility security, information system vulnerabilities, and reliance on key facilities. Financially, liquidity ratios indicate tight short-term coverage, and ongoing legal and arbitration costs related to Duke may strain resources. The outcome of strategic alternatives and the Celle subsidiary spinoff remain uncertain.

Cryo-Cell's competitive moat is anchored in its pioneering status as the first private cord blood bank, extensive specimen inventory exceeding 250,000 units, and its FDA-compliant, cGMP/cGTP-certified facilities with AABB and FACT accreditations. The company employs advanced processing technology that maximizes healthy stem cell recovery and offers unique features such as a five-compartment freezer bag and a payment warranty for engraftment failure. Its established client base, national educational outreach, and international licensing agreements further support market penetration. The combination of regulatory compliance, technological differentiation, and operational scale creates barriers to entry and competitive advantages in the cord blood storage and processing market.

• Duke License Agreement Dispute: The termination of the Duke License Agreement in May 2025 has halted investments in related clinical and biopharmaceutical initiatives, paused the opening of the Cryo-Cell Institute for Cellular Therapies, and put the Celle Corp. spinoff on hold. The outcome of arbitration and legal proceedings with Duke presents material uncertainty.
• Competitive and Regulatory Risks: Increasing competition from public cord blood banks, especially internationally, and potential regulatory changes in stem cell storage and processing could adversely affect the company's market position and operating margins.
• Operational Risks: Risks include potential failures or compromises in storage facilities, information systems security breaches, natural disasters, and other disruptions that could impact specimen integrity and company reputation.
• Financial and Liquidity Risks: The company’s current ratio of 0.71 and cash ratio of 0.2 as of May 31, 2026 indicate limited short-term liquidity. Dependence on credit facilities and the need for additional financing to support operations and strategic initiatives pose risks if capital is not available on favorable terms.

• Cryo-Cell International, Inc. is a Delaware corporation incorporated in 1989 and was the world's first private cord blood bank to separate and store stem cells in 1992 [S1].
• The company operates three reportable segments: (1) cellular processing and cryogenic storage for family use focusing on umbilical cord blood and tissue stem cells, (2) manufacture of PrepaCyte® CB Processing System units used to process umbilical cord blood stem cells, and (3) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use [S1].
• Cryo-Cell and its global affiliates store over 250,000 cord blood and cord tissue specimens worldwide for the benefit of newborns and possibly their families [S1].
• The company’s U.S. operations, including processing and storage, are headquartered in Oldsmar, Florida, with specimens primarily stored in a technologically advanced facility in Durham, North Carolina [S1].
• Cryo-Cell offers cord blood and cord tissue storage services, charging fees for processing, testing, and storage with options for annual fees or prepaid plans [S1].
• The company’s facilities comply with FDA regulations (21 CFR Part 1271), Good Manufacturing Practice (cGMP), and Good Tissue Practice (cGTP), and have AABB and FACT accreditations [S1].
• Competitive advantages include: the first private cord blood bank status, cGMP/cGTP compliance, AABB and FACT accreditation, advanced processing technology yielding maximum healthy stem cell recovery, a five-compartment cord blood freezer bag, secure storage environment, 100% specimen viability upon thaw, 7-day processing capability, and a payment warranty for engraftment failure [S1].
• The company introduced a cord tissue service in 2011, storing a section of umbilical cord tissue rich in mesenchymal stromal cells (MSCs) with potential regenerative properties [S1].
• Cryo-Cell acquired assets of Cord:Use Cord Blood Bank in 2018, expanding its public cord blood banking inventory, which is sold through the National Marrow Donor Program (NMDP) [S1].
• The company purchased a 56,000 square-foot facility in Durham, NC, to support storage needs, third-party storage services (ExtraVault), and cellular therapy laboratory operations [S1].
• Cryo-Cell had a Patent and Technology License Agreement with Duke University (Duke License Agreement) to develop cord blood and tissue therapies and biopharmaceutical manufacturing, but Duke terminated the agreement effective May 17, 2025, causing a pause in related investments and the proposed spinoff of Celle Corp. [S1, S2].
• The company recorded a $13.1 million impairment charge related to the Duke License Agreement assets in fiscal 2023 [S1].
• Cryo-Cell markets its services through online advertising and a national team of field cord blood educators, with many new enrollments generated from returning customers and referrals [S1].
• The company has license agreements to market its cord blood stem cell programs in several Central American countries including Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama [S1].
• Financial snapshot as of May 31, 2026: cash and equivalents $507,302; short-term investments $2,654,665; current assets $11,304,354; current liabilities $15,929,889; current ratio 0.71; cash ratio 0.2 [S2].
• Revenue for the three months ended May 31, 2026 was approximately $7.78 million, a 2% decrease from the prior year period; net income for the six months ended May 31, 2026 was $554,586; basic and diluted EPS were $0.07 [S2].
• The company’s revenue primarily derives from processing and storage fees for cord blood and tissue specimens, with some product and public cord blood banking revenue [S2].
• Operating expenses include selling, general and administrative expenses, research and development, depreciation, and interest expense related to credit agreements [S2].
• The company has a revolving credit facility and term loan with Susser Bank, with interest rate swap agreements to manage variable rate debt exposure [S2].
• Risks include uncertainties related to the Duke License Agreement dispute and arbitration, competition from public cord blood banks, regulatory changes, technological obsolescence, operational risks including facility security and information systems, and the ability to finance operations and strategic initiatives [S1, S2].
• Recent news highlights include a Q3 profit drop reported in October 2025, insider buying activity reported in 2025, trading halts and resumptions in late 2024, and plans to explore strategic alternatives and a Celle subsidiary spinoff announced in March 2024 [N1, N2, N3, N4, N5, N6, N8].